Mindset Pharma Inc
Change company Symbol lookup
Select an option...
MSSTF Mindset Pharma Inc
MOS Mosaic Co
FRC-H First Republic Bank
VYM Vanguard High Dividend Yield Index Fund ETF Shares
SMBC Southern Missouri Bancorp Inc
ALG Alamo Group Inc
AFFCF American Future Fuel Corp
TDS-U Telephone and Data Systems Inc
FRSH Freshworks Inc
TA Travelcenters of America Inc
Go

Health Care : Pharmaceuticals |
Based in Canada
Company profile

Mindset Pharma Inc. is a Canada-based drug discovery and development company. The Company is engaged in the psychedelic-based drug discovery business focused on creating patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.

Closing Price
$0.30
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
2,116

10-day average volume:
9,572
2,116

Company Profile

Mindset Pharma Inc. is a Canada-based drug discovery and development company. The Company is engaged in the psychedelic-based drug discovery business focused on creating patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
14.38x
Price/Book (MRQ)
21.06x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

No short interest available.

Share Information

MSSTF is in a share class of common stock
Float
62.7M
Shares Outstanding
82.4M
Institutions Holding Shares
3
1.63%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.